[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
October 10, 2012

Computed Tomographic Screening for Lung Cancer: An Opportunity to Evaluate Other Diseases

Author Affiliations

Author Affiliations: Department of Radiology, University Medical Center Utrecht, Utrecht, the Netherlands (Drs Mets and de Jong); and Department of Radiology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands (Dr Prokop).

JAMA. 2012;308(14):1433-1434. doi:10.1001/jama.2012.12656

The results of the National Lung Screening Trial (NLST) have led to renewed interest in lung cancer screening. The NLST demonstrated that lung cancer screening using computed tomography (CT) reduces lung cancer–specific mortality by more than 20% and overall mortality by 7%.1 Although the discussion about false-positive findings is unsettling and cost-effectiveness analysis and confirmation by other large randomized trials are still being awaited, guidelines have been released by major organizations in the United States recommending lung cancer screening for patients who meet the inclusion criteria of the NLST.2